ESMO 2025: Key Advances in Non-Muscle-Invasive Bladder Cancer Shape Future Oncology Strategies

Key Takeaways

• POTOMAC (NCT03528694): durvalumab + BCG induction and maintenance vs BCG alone; DFS HR 0.68 (32% risk reduction); 1,018 patients; median follow-up 60.7 months (The Lancet).
• ALBAN (NCT03799835): atezolizumab + BCG vs BCG alone missed primary EFS (HR 0.98; p=0.9106) in BCG-naive high-risk NMIBC.
• Durvalumab + BCG induction-only did not beat BCG induction and maintenance on DFS in POTOMAC—maintenance BCG mattered.
• Checkpoint-plus-BCG is not a class effect; underwrite each agent and schedule separately.

What did POTOMAC actually report at ESMO 2025?

POTOMAC randomised 1,018 BCG-naive patients with high-risk NMIBC after TURBT to three arms: durvalumab plus BCG induction and maintenance, durvalumab plus BCG induction only, or BCG induction and maintenance.

Per the simultaneous Lancet final analysis, durvalumab plus BCG induction and maintenance delivered a 32% reduction in high-risk recurrence or death versus BCG alone (HR 0.68; 95% CI 0.50–0.93; log-rank p=0.015) at median follow-up 60.7 months. Median DFS was not reached in either arm. Grade 3–4 treatment-related adverse events were higher with the combination (21% vs 4% in the BCG comparator among treated patients).

Trial registration and design details are on ClinicalTrials.gov NCT03528694.

Did ALBAN confirm a PD-L1 class effect in NMIBC?

No. ALBAN is not an antibody-drug conjugate study and did not report biomarker-selected ADC responses.

ALBAN (GETUG-AFU 37) compared intravenous atezolizumab plus one-year intravesical BCG with BCG alone in BCG-naive high-risk NMIBC. The primary endpoint was investigator-assessed event-free survival. PubMed’s summary of the Annals of Oncology publication states the trial did not meet that endpoint: EFS HR 0.98 (95% CI 0.71–1.36; p=0.9106), with consistent results across prespecified subgroups and higher treatment-related adverse event rates on the combination.

Protocol identity and enrolment are recorded on ClinicalTrials.gov NCT03799835 and in the PubMed abstract (PMID 41110692).

How should BD and investors read the ESMO 2025 split?

The commercial signal is differential, not uniform oncology expansion.

• Programmes that can replicate POTOMAC’s schedule (PD-L1 + BCG induction and maintenance) gain a clearer registrational story in BCG-naive high-risk NMIBC.
• Assets that look like ALBAN’s design need a new thesis—biomarker enrichment, dosing, or route—not a generic “IO + BCG” pitch.
• Historical BCG failure rates of roughly 30%–40% still define the residual unmet need after either readout.

For pipeline maps, pair these readouts with broader bladder cancer coverage such as Key cancer drugs at ESMO 2025 and disease context on oncology.

What remains unproven after ESMO 2025?

POTOMAC supports DFS benefit for one year of durvalumab with BCG induction and maintenance, but overall survival was not the primary win metric, and regulatory labels, payer criteria, and cystectomy-sparing claims still require agency review of the full package.

ALBAN’s negative EFS result means atezolizumab plus BCG should not be modelled as a near-term standard in BCG-naive high-risk NMIBC on this dataset. Cross-trial comparisons between POTOMAC and ALBAN are limited by different primary endpoints (DFS vs EFS), sponsors, and geographies.

NMIBC market context for oncology portfolios

Roughly three-quarters of newly diagnosed bladder cancers present as non-muscle-invasive disease, so earlier-line PD-(L)1 combinations can expand addressable populations far beyond metastatic urothelial carcinoma franchises.

That scale only converts if Phase III endpoints, BCG maintenance duration, and safety burden clear regulators and guidelines. The ESMO 2025 pair shows why diligence must cite primary numbers—HR 0.68 on POTOMAC DFS versus HR 0.98 on ALBAN EFS—rather than conference headlines that blur positive and negative PD-L1 trials.

Related NovaPharma coverage

• Insights from ESMO Asia: Nadia Harbeck on oncology advances
• Key cancer drugs to watch at ESMO 2025
• Hayes receives 2026 ESMO Breast Cancer Award

Frequently Asked Questions

Primary Sources

1. The Lancet — POTOMAC Phase III final analysis
2. ClinicalTrials.gov — POTOMAC (NCT03528694)
3. ClinicalTrials.gov — ALBAN (NCT03799835)
4. PubMed — ALBAN GETUG-AFU 37 (PMID 41110692)